ArticleCell metabolism2020
Disulfiram Treatment Normalizes Body Weight in Obese Mice.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Cell metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05162001 (Body Weight Response With Disulfiram in Humans. Concept Testing Study), which is not on this map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05162001 early_phase1unknown statusnot on this mapstarted 2021, after this paper: background citation
Body Weight Response With Disulfiram in Humans. Concept Testing Study
Who cites it
52 citing papers in PubMed, 86 citations in OpenAlex.
- Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism.Nature communications · 2022Trial
- Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence.iScience · 2026Article
- Disulfiram attenuates immobilization-induced knee joint contracture by suppressing Caspase-1/GSDMD-mediated pyroptosis.Scientific reports · 2026Article
- FDA-approved drug library screen identifies antidepressants, antimicrobials, anti-COPD, and anti-CVD agents as blockers of NLRP3 inflammasome and sepsis in a sex-dependent manner.bioRxiv : the preprint server for biology · 2026Article
- Disulfiram Protects Against Diet-Induced Obesity by Reprogramming Systemic Lipid Partitioning Independent of GSDMD.bioRxiv : the preprint server for biology · 2026Article
- Disulfiram and Its Derivatives: An Immortal Phoenix of Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Disulfiram inhibits Gasdermin D pores formation and improves insulin-dependent glucose uptake and glucose homeostasis in skeletal muscle of obesity-induced insulin-resistant mice.Scientific reports · 2025Article
- Cuproptosis: a novel therapeutic mechanism in lung cancer.Cancer cell international · 2025Review
- Targeting Hyperuricemia and NLRP3 Inflammasome in Gouty Arthritis: A Preclinical Evaluation of Allopurinol and Disulfiram Combination Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Disulfiram in liver diseases: a double-edged sword.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Disulfiram inhibits bacterial growth by inducing zinc-dependent reactive oxygen species.Frontiers in microbiology · 2025Article
- A New Strategy for Obesity Treatment: Revealing the Frontiers of Anti-obesity Medications.Current molecular medicine · 2025Review
- Article
- Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells.Molecular cancer · 2024Article
- AuCePt porous hollow cascade nanozymes targeted delivery of disulfiram for alleviating hepatic insulin resistance.Journal of nanobiotechnology · 2024Article
- The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes.The Journal of experimental medicine · 2024Review
- Gene body DNA hydroxymethylation restricts the magnitude of transcriptional changes during aging.Nature communications · 2024Article
- Disulfiram Reduces Atherosclerosis and Enhances Efferocytosis, Autophagy, and Atheroprotective Gut Microbiota in Hyperlipidemic Mice.Journal of the American Heart Association · 2024Article
- The gasdermin family: emerging therapeutic targets in diseases.Signal transduction and targeted therapy · 2024Review
- Disulfiram-Loaded Nanoparticles Inhibit Long-Term Proliferation on Preadipocytes.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 6 institutions in 3 countries.
Michel BernierExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA. Electronic address: bernierm@mail.nih.gov.
Sarah J MitchellExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Devin WahlExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Ageing and Alzheimer's Institute, ANZAC Research Institute, Concord Clinical School/Sydney Medical School, Concord, NSW 2139, Australia.
Antonio DiazDepartment of Developmental and Molecular Biology, Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA.
Abhishek SinghVascular Biology and Therapeutics Program, Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Wonhyo SeoLaboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA.
Mingy WangLaboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Ahmed AliExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Tamzin KaiserExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Nathan L PriceVascular Biology and Therapeutics Program, Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Miguel A AonExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA; Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Eun-Young KimExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA; Functional Genomics Research Center, KRIBB, Daejeon 305-806, Republic of Korea.
Michael A PetrExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Huan CaiLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Alessa WarrenAgeing and Alzheimer's Institute, ANZAC Research Institute, Concord Clinical School/Sydney Medical School, Concord, NSW 2139, Australia.
Clara Di GermanioExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Andrea Di FrancescoExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Ken FishbeinLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Vince GuiterrezExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Dylan HarneyCharles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.
Yen Chin KoayCharles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Heart Research Institute, The University of Sydney, Sydney, NSW 2042, Australia.
John MachKolling Institute of Medical Research and Sydney Medical School, University of Sydney, Sydney, NSW 2065, Australia.
Ignacio Navas EnamoradoExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Tamara PulpitelCharles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Ageing and Alzheimer's Institute, ANZAC Research Institute, Concord Clinical School/Sydney Medical School, Concord, NSW 2139, Australia.
Yushi WangLaboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Jing ZhangLaboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Li ZhangLaboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Richard G SpencerLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Kevin G BeckerLaboratory of Genetics, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Josephine M EganLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Edward G LakattaLaboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
John O'SullivanCharles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Heart Research Institute, The University of Sydney, Sydney, NSW 2042, Australia.
Mark LaranceCharles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.
David G LeCouteurCharles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Ageing and Alzheimer's Institute, ANZAC Research Institute, Concord Clinical School/Sydney Medical School, Concord, NSW 2139, Australia.
Victoria C CoggerCharles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Ageing and Alzheimer's Institute, ANZAC Research Institute, Concord Clinical School/Sydney Medical School, Concord, NSW 2139, Australia.
Bin GaoLaboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA.
Carlos Fernandez-HernandoVascular Biology and Therapeutics Program, Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Ana Maria CuervoDepartment of Developmental and Molecular Biology, Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA.
Rafael de CaboExperimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA. Electronic address: decaboRa@mail.nih.gov.
National Institutes of Health · USNational Institute on Aging · USThe University of Sydney · AUYale University · USAlbert Einstein College of Medicine · USAnzac Research Institute · AU
Funding
Role of Autophagy in T Cell Function and Immunosenescence (Project 3)P01AG031782 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CUERVO, ANA MARIA · 2009 to 2024
$36.2MStable Isotope and Metabolomics CoreP60DK020541 · NIDDK · YESHIVA UNIVERSITY · PI PESSIN, JEFFREY E. · 1986 to 2014
$29.8MTranslational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI STREAMSON C CHUA · 2015 to 2026
$27.7MMolecular mechanisms of liver injury, repair, and immunityZIAAA000368 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI GAO, BIN · 2009 to 2023
$16.1MEinstein's Nathan Shock Center of Excellence in Basic Biology of AgingP30AG038072 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HUFFMAN, DEREK MAJOR · 2010 to 2024
$10.8MAging Intervention ProgramZIAAG000363 · NIA · NATIONAL INSTITUTE ON AGING · PI DE CABO, RAFAEL · 2009 to 2025
$9.0MNovel insights into the molecular and cellular mechanism regulating lipid metabolism and atherosclerosisR35HL135820 · NHLBI · YALE UNIVERSITY · PI FERNANDEZ HERNANDO, CARLOS · 2017 to 2023
$6.0MControl of vesicular trafficking in the hepatocyte.R01DK098408 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CUERVO, ANA MARIA, WOLKOFF, ALLAN W · 2013 to 2022
$5.6MDecreased Protein Degradation in AgingR37AG021904 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CUERVO, ANA MARIA · 2013 to 2022
$4.4MDECREASED PROTEIN DEGRADATION IN AGINGR01AG021904 · NIA · YESHIVA UNIVERSITY · PI CUERVO, ANA MARIA · 2003 to 2012
$3.7MUnderstanding Alzheimer's Disease in the Context of the Aging BrainRF1AG054108 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CUERVO, ANA MARIA · 2016 to 2016
$2.1MIntramural NIH HHS Z99 AG999999NHLBI NIH HHS R35 HL135820NIA NIH HHS P01 AG031782NIA NIH HHS P30 AG038072NIA NIH HHS R01 AG021904NIA NIH HHS R37 AG021904NIA NIH HHS RF1 AG054108NIDDK NIH HHS P30 DK020541NIDDK NIH HHS P60 DK020541NIDDK NIH HHS R01 DK098408
Abstract
Obesity is a top public health concern, and a molecule that safely treats obesity is urgently needed. Disulfiram (known commercially as Antabuse), an FDA-approved treatment for chronic alcohol addiction, exhibits anti-inflammatory properties and helps protect against certain types of cancer. Here, we show that in mice disulfiram treatment prevented body weight gain and abrogated the adverse impact of an obesogenic diet on insulin responsiveness while mitigating liver steatosis and pancreatic islet hypertrophy. Additionally, disulfiram treatment reversed established diet-induced obesity and metabolic dysfunctions in middle-aged mice. Reductions in feeding efficiency and increases in energy expenditure were associated with body weight regulation in response to long-term disulfiram treatment. Loss of fat tissue and an increase in liver fenestrations were also observed in rats on disulfiram. Given the potent anti-obesogenic effects in rodents, repurposing disulfiram in the clinic could represent a new strategy to treat obesity and its metabolic comorbidities.
Indexed as
AnimalsAnti-Obesity AgentsBody WeightDietDisulfiramFemaleMaleMiceMice, Inbred C57BLMice, KnockoutObesityRatsRats, Sprague-DawleyAnti-Obesity AgentsDisulfirambeta-cell hyperplasiafibrosishepatic steatosisinflammationinsulin resistanceobesityweight gain
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05162001ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.